Govt must indemnify vaccine makers against all lawsuits: Adar Poonawalla

Vaccine makers are going to propose this to the government, he says

Adar Poonawalla, CEO, Serum Institute
Adar Poonawalla, CEO, Serum Institute
Press Trust of India New Delhi
2 min read Last Updated : Dec 19 2020 | 7:00 PM IST

Vaccine manufacturers need to have protection against all lawsuits for their vaccines especially during a pandemic, Serum Institute of India (SII) Chief Executive Officer Adar Poonawalla has said.

He also said that the vaccine makers are going to propose this to the government, while speaking at a virtual panel on the challenges of developing a Covid-19 vaccine at the Carnegie India's Global Technology Summit on Friday.

"We need to have the government indemnify manufacturers, especially vaccine manufacturers, against all lawsuits. In fact, COVAX and other countries have already started talking about that," Poonawalla said.

It is because when frivolous claims come up, and something is blown out of proportion in the media, skepticism sets in that definitely something can happen due to the vaccine and to dispel that, the government needs to step in to spread the right information, he added.

"..the government can act, the US, for example, has in fact invoked a law, to say that during a pandemic, and this is especially important only during a pandemic, to indemnify vaccine manufacturers against lawsuits for severe adverse effects or any other frivolous claims which may come about, because that adds to the fear and also will bankrupt vaccine manufacturers or distract them if they have to just all day fight lawsuits and explain to the media what is happening," Poonawalla said.

These are a few things that the government can do and that is what the vaccine manufacturers are going to propose, he added.

Last month, Serum had rejected charges that a 40-year-old man who took part in the 'Covishield' vaccine trial in Chennai had levelled against the company, alleging serious side effects, including a virtual neurological breakdown and impairment of cognitive functions.

He had also sought Rs 5 crore compensation in a legal notice to Serum and others, besides seeking a halt on the trial.

Refuting the charges, Serum had said, "It is evident that the intention behind spreading of such malicious information is an oblique pecuniary motive. The Serum Institute of India, will seek damages in excess of Rs 100 crore for the same and will defend such malicious claims".

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: Dec 19 2020 | 5:48 PM IST

Next Story